Cover Image
市場調查報告書

個人化醫療和表觀基因:各種技術和全球市場

Personalized Medicine and Epigenomics: Technologies and Global Markets

出版商 BCC Research 商品編碼 354337
出版日期 內容資訊 英文 227 Pages
訂單完成後即時交付
價格
Back to Top
個人化醫療和表觀基因:各種技術和全球市場 Personalized Medicine and Epigenomics: Technologies and Global Markets
出版日期: 2016年03月14日 內容資訊: 英文 227 Pages
簡介

全球表觀基因市場2014年約40億美元,2015年記錄47億美元的規模。預計從2015年到2020年以20.6%的年複合成長率 (CAGR) 發展,2020年成長到近121億美元的規模。

本報告提供全球個人化醫療和表觀基因的技術及市場調查,表觀基因定義和概要,表觀基因和個人化醫療的主要趨勢,市場影響因素分析,各產品、技術、用途、疾病區分、地區的市場分析及預測,以及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 表觀基因的新範例
  • 診斷
  • 藥物
  • 成長推進因素
  • 生命科學部門的資金供給的擴大
  • 表觀基因地圖創造
  • 先進各國的高齡化
  • 更佳的癌症治療需求
  • 個人化醫療的成長
  • 表觀遺傳學技術的重要性
  • 表觀基因技術的生命週期狀況
    • 歷史背景
    • 表觀基因產業

第4章 已上市、正在開發的表觀遺傳藥

  • 概要
  • 藥物的分類
    • DNMT抑制劑
    • DNA甲基化
    • 組蛋白去乙醯酶抑制劑
  • 新的治療方法
  • 大規模地區的表觀基因計劃

第5章 治療藥為基礎的個人化醫療

  • 概要
  • 市場動態
  • 癌症的表觀遺傳個體化治療藥
    • 血液癌症
    • 固態腫瘤
    • 胃癌
    • 肺癌
    • 大腸癌
  • 精神疾病的表觀遺傳個體化治療藥
    • 亨丁頓舞蹈症
    • 老年癡呆症
    • 憂鬱症
    • 精神遲緩
    • 帕金森氏病
  • 心臟血管疾病的表觀遺傳個體化治療藥
  • 其他表觀遺傳個體化治療藥
    • 骨髓發育不良症候群
    • 肥胖症
    • 糖尿病
    • 類風濕性關節炎
    • 多發性硬化症
    • 發炎性腸道疾病

第6章 表觀遺傳治療

  • 幹細胞治療
  • 糖尿病
  • 精神疾病
    • 季節性感情障礙
    • 單極性憂鬱症
    • 輕鬱症
    • 非定型憂鬱症
    • 精神病性憂鬱症

第7章 生物標記技術

  • 生物標記的發現:癌症檢測DNA的甲基化的DNA甲基化
  • 市場動態

第8章 癌症之外的表觀遺傳診斷

  • 神經疾病
    • 老年癡呆症
  • R&D
    • 憂鬱症
    • 精神遲緩
  • 心血管疾病
  • 心臟疾病
  • 發炎性疾病、自體免疫性疾病
    • 類風濕性關節炎
    • 糖尿病
    • 多發性硬化症
    • 發炎性腸道疾病
    • 狼瘡
  • R&D
    • 癌症檢測的DNA甲基化
    • 診斷、預期的表觀遺傳生物標記的檢測
    • 表觀遺傳基因抑制的機制

第9章 表觀遺傳學的用途

  • 初期胚階段的表觀遺傳學
  • 表觀遺傳再編程的動物健康、食品消費風險的影響
  • 再編程係數
  • 培養的間充質幹細胞的表觀遺傳簡介

第10章 表觀基因:地區分析

  • 概要
    • 北美
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲

第11章 產品分析

  • 試劑
  • 套件
  • 設備
  • 酵素
  • 服務

第12章 分析:各技術

  • DNA甲基化
    • 組蛋白的甲基化、乙醯化
    • miRNA的修飾

第13章 分析:各用途

  • 癌症
  • 癌症之外
  • 癌症治療藥技術
    • DNA甲基轉移酵素抑制劑
  • 組蛋白去乙醯酶抑制劑
  • 適應區域
    • 診斷
    • 預後
  • 臨床治療例行性中治療的最佳化
    • 藥物研發

第14章 分析:各類個體化治療藥物

  • 心血管疾病
  • 精神疾病
  • 其他
  • 癌症檢測生物標記的組蛋白修飾

第15章 企業簡介

  • ABBOTT LABORATORIES
  • AFFYMETRIX
  • AGILENT TECHNOLOGIES
  • Astellas Pharma Inc.
  • BAYER AG
  • BIO VISION
  • CELGENE CORP.
  • EMD MILLIPORE
  • EPIGENOMICS AG
  • EPIGENTEX
  • ENVIVO PHARMACEUTICALS (FORUM PHARMACEUTRICALS)
  • GILEAD SCIENCES
  • GLAXOSMITHKLINE
  • ILLUMINA INC.
  • JOHNSON & JOHNSON
  • KARUS THERAPEUTICS LIMITED
  • LABORATORY CORP. OF AMERICA HOLDINGS
  • LES LABORATOIRES SERVIER
  • MERCK SHARP & DOHME
  • NATUREWISE BIOTECH & MEDICALS CORP.
  • NOVARTIS PHARMA AG
  • ONCOLYS BIOPHARMA INC.
  • ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
  • PROGEN PHARMACEUTICALS LIMITED
  • QUEST DIAGNOSTICS
  • ROCHE HOLDING AG
  • RUBICON GENOMICS
  • 武田藥品工業

第16章 專利分析

  • 美國
  • 歐洲、日本

圖表

目錄
Product Code: PHM044C

REPORT HIGHLIGHTS

The global epigenomic market reached nearly $4 billion in 2014 and $4.7 billion in 2015. The market should reach nearly $12.1 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 20.6% from 2015 to 2020.

This report provides:

  • An overview of the global markets and technologies for personalized medicine and epigenomics.
  • Analyses global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Analysis of the current personalized medicine business model and the commercial use of the personalized medicine technology platform.
  • Evaluation of individual submarkets for personalized medicine in terms of technology, products, services, application areas and geography.
  • A look at the market's dynamics, specifically growth drivers, restraints, and opportunities.
  • Profiles of major players in the industry.

SCOPE OF THE REPORT

The report will analyze the market by types, products and applications. It will also focus on emerging technologies and therapies. Geographically, the market is divided into five regions: North America, Europe, the Asia-Pacific region and Latin America, and the Middle East and Asia (MEA).

  • Products are segmented by reagents, kits, instruments, enzymes and services.
  • Technologies are segmented by DNA methylation, histone methylation and acetylation, MicroRNA modification.
  • Applications are segmented areas by diagnosis, prognosis, therapy optimization in routine clinical treatment and drug discovery.
  • Therapy areas are segmented by cancer treatment, neurological disorders, CVD and others, which includes the research and development (R&D) stage.
  • Cancer treatment is further broken down into hematological cancers, solid tumors, gastric cancer, lung cancer and others.

ANALYST'S CREDENTIALS

Vijay Laxmi has more than 20 years of domain experience. In addition to business research and consulting, she has conducted corporate briefings for top players in a wide range of market segments. She has worked with major market research firms and handled projects for various consultancies. She has authored market research studies in the healthcare domain on such subjects.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVE
  • TITLE DESCRIPTION
  • SCOPE OF THE REPORT
  • INTENDED AUDIENCE
  • RESEARCH METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 ($ MILLIONS)

CHAPTER 3 - MARKET OVERVIEW

  • INTRODUCTION
  • NEW PARADIGM OF EPIGENOMICS
    • EPIGENOMICS AS IT FITS WITHIN GENOMICS
    • TECHNICAL SCOPE OF THIS REPORT
    • EPIGENOMIC MARKET POTENTIAL
    • EPIGENOMIC PRODUCTS
    • RESEARCH TOOLS AND REAGENTS
  • DIAGNOSTICS
  • DRUGS
    • TABLE 1: U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES
    • TABLE 2: SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT
  • GROWTH DRIVING FORCES
  • GROWTH IN LIFE SCIENCE FUNDING
  • EPIGENOMIC MAP CREATION
  • AGING POPULATIONS IN DEVELOPED COUNTRIES
  • NEED FOR BETTER CANCER THERAPIES
  • GROWTH IN PERSONALIZED MEDICINE
  • IMPORTANCE OF EPIGENETIC TECHNOLOGY
  • LIFECYCLE STATUS OF EPIGENOMIC TECHNOLOGIES
    • HISTORICAL BACKGROUND
    • EPIGENOMIC INDUSTRY

CHAPTER 4 - EPIGENETIC DRUGS ON THE MARKET AND IN THE PIPELINE

  • OVERVIEW
  • DRUG CLASSIFICATION
    • TABLE 3: EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL
    • DNMT INHIBITORS
      • Nucleoside Analogue Inhibitors
      • Non-Nucleoside Analogue Inhibitors
      • Antisense Oligonucleotides
        • TABLE 4: CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND DEVELOPMENTAL PHASES, 2005-2015
  • DNA METHYLATION
    • DNA Methyltransferases
      • FIGURE 1: AZAC AND 5-AZADC MECHANISM OF ACTION
  • HISTONE DEACETYLASE INHIBITORS
    • Histone Deacetylase Inhibitors' Roles in Mental Health
    • Histone Deacetylase Inhibitors Roles in Other Health Conditions
    • Epigenetic Drug Combinations
      • FIGURE 2: EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC GENES
  • EMERGING THERAPIES
  • LARGE-SCALE REGIONAL EPIGENOMIC PROJECTS
    • ENCYCLOPEDIA OF DNA ELEMENTS
    • INTERNATIONAL HUMAN EPIGENOME CONSORTIUM
      • Blueprint
      • Epigenomic Platform Program (Canada)
      • DEEP (Germany)
      • CREST/IHEC, Team Japan (Asia)
      • National Institutes of Health Roadmap Epigenomic Project
    • OTHER REGIONAL PROJECTS
      • Asia-Pacific Projects
      • Canadian and Australian Projects
      • European Epigenomic Projects

CHAPTER 5 PERSONALIZED MEDICINE BASED ON THERAPEUTICS

  • OVERVIEW
  • MARKET DYNAMICS
    • FIGURE 3: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020
  • EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT
    • HEMATOLOGICAL CANCERS
      • TABLE 5: FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES, 2004-2015
      • SOLID TUMORS
      • GASTRIC CANCER
      • LUNG CANCER
      • COLORECTAL CANCERS
  • EPIGENETIC PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS
    • HUNTINGTON'S DISEASE
    • ALZHEIMER'S DISEASE
    • DEPRESSION
    • MENTAL RETARDATION
    • PARKINSON'S DISEASE
    • EPIGENETIC PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASES
    • EPIGENETIC PERSONALIZED MEDICINE FOR OTHERS
      • MYELODYSPLASTIC SYNDROMES
        • TABLE 6: CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC SYNDROMES (2015)
    • OBESITY
    • DIABETES
    • RHEUMATOID ARTHRITIS
    • MULTIPLE SCLEROSIS
      • TABLE 7: EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS PATHOGENESIS
    • INFLAMMATORY BOWEL DISEASES

CHAPTER 6 EPIGENETIC THERAPIES

  • STEM CELL THERAPIES
  • DIABETES
  • MENTAL DISORDERS
    • SEASONAL AFFECTIVE DISORDER
    • UNIPOLAR DEPRESSION
    • DYSTHYMIA OR DYSTHYMIA DISORDER
    • ATYPICAL DEPRESSION
    • PSYCHOTIC DEPRESSION

CHAPTER 7 BIOMARKER TECHNIQUES

  • BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION DNA METHYLATION
    • CHROMATIN REMODELING
    • MIRNAS
      • miRNA Detection
  • MARKET DYNAMICS FOR EPIGENETIC DRUGS AND BIOMARKER DISCOVERY
    • DRIVERS
      • Increasing Prevalence of Cancer and Other Chronic Diseases
        • TABLE 8: GLOBAL CANCER INCIDENCES, 2012
      • Growing Global Geriatric Population Base
        • FIGURE 4: POPULATION AGE 65 AND OLDER, 2010-2030 (%)
      • Increasing Collaborations between Biotechnology and Pharmaceutical Companies and Academic Research Institutes
        • TABLE 9: MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015
      • Presence of Funding Programs to Promote and Support Research and Development
        • TABLE 10: KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED R&D, 2004-2015
      • Introduction of Technological Advancements
    • RESTRAINTS
      • Inefficiency to Identification and Validation of Biomarkers
      • Presence of Complicated Regulatory Framework

CHAPTER 8 EPIGENETIC NON-CANCER DIAGNOSIS

  • FIGURE 5: EPIGENOMIC ANALYSIS
  • NEURO
    • ALZHEIMER'S DISEASE
  • RESEARCH AND DEVELOPMENT
    • DEPRESSION
    • MENTAL RETARDATION
  • CARDIOVASCULAR DISEASE
    • TABLE 11: GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS)
    • FIGURE 6: POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%)
    • FIGURE 7: GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%)
  • RESEARCH AND DEVELOPMENT IN EPIGENETICS CREATING HUGE SCOPE
    • FIGURE 8 EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES
  • HEART FAILURE
  • INFLAMMATORY AND AUTOIMMUNE DISEASE
    • RHEUMATOID ARTHRITIS
    • DIABETES
    • MULTIPLE SCLEROSIS
      • FIGURE 9: EPIGENETICS MECHANISM
    • INFLAMMATORY BOWEL DISEASES
    • LUPUS
  • RESEARCH AND DEVELOPMENT
    • DNA METHYLATION IN CANCER DETECTION
    • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
    • MECHANISMS OF EPIGENETIC GENE SILENCING

CHAPTER 9 EPIGENETIC APPLICATIONS

  • EPIGENETICS DURING EARLY EMBRYONIC STAGES
    • PRE-IMPLANTATION REPROGRAMMING
      • Fusion and Cleavage
      • Demethylation and Remethylation in Early Embryos
      • Epigenetic Reprogramming in Later Development
      • Gene Expression and its Development in Clones and Technical Contributions
    • GAMETOGENIC REPROGRAMMING
    • MITOCHONDRIAL HETEROPLASMY
  • IMPLICATIONS OF EPIGENETIC REPROGRAMMING ON ANIMAL HEALTH AND FOOD CONSUMPTION RISKS
  • REPROGRAMMING FACTORS
  • EPIGENETIC PROFILE OF MESENCHYMAL STEM CELLS IN CULTURE
    • TABLE 12: INDICATIONS AND OUTCOMES

CHAPTER 10 EPIGENOMICS: REGIONAL ANALYSIS

  • OVERVIEW
    • NORTH AMERICA
      • FIGURE 10: NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
      • TABLE 13: NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
      • TABLE 14: NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 15: NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 16: NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 17: NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
      • TABLE 18: NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)
      • TABLE 19: NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 20: NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
      • TABLE 21: NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 22: NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 23: NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 24: NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 25: NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
      • TABLE 26: NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 27: NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 28: NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 29: NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 30: NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • ASIA-PACIFIC
      • FIGURE 11: ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
      • TABLE 31: ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
      • TABLE 32: ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 33: ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 34: ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 35: ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 36: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 37: ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 38: ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY THERAPEUTIC, THROUGH 2020 ($ MILLIONS)
      • TABLE 39: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 40: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 41: ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 42: ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 43: ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 44: ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 45: ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 46: ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 47: ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 48: ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • EUROPE
      • FIGURE 12: EUROPE EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
      • TABLE 49: EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
      • TABLE 50: EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH ($ MILLIONS)
      • TABLE 51: EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 52: EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 53: EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
      • TABLE 54: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 55: EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 56: EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
      • TABLE 57: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 58: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 59: EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 60: EUROPEAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 61: EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
      • TABLE 62: EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 63: EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 64: EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 65: EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 66: EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • LATIN AMERICA
      • FIGURE 13: LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
      • TABLE 67: LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
      • TABLE 68: LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 69: LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 70: LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 71: LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 72: LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 73: LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 74: LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
      • TABLE 75: LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 76: LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 77: LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 78: LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 79: LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 80: LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 81: LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 82: LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 83: LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 84: LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • MIDDLE EAST AND AFRICA
      • FIGURE 14: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
      • TABLE 85: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
      • TABLE 86: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 87: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
      • TABLE 88: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
      • TABLE 89: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
      • TABLE 90: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 ($ MILLIONS)
      • TABLE 91: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
      • TABLE 92: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
      • TABLE 93: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
      • TABLE 94: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
      • TABLE 95: MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 96: MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 97: MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 98: MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 99: MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 100: MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 101: MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
      • TABLE 102: MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)

CHAPTER 11 PRODUCT ANALYSIS

  • REAGENTS
    • FIGURE 15: GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 ($ MILLIONS)
    • TABLE 103: GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
  • KITS
    • FIGURE 16: GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 ($ MILLIONS)
    • TABLE 104: GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 ($ MILLIONS)
  • INSTRUMENTS
    • FIGURE 17: GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 ($ MILLIONS)
    • TABLE 105: GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION, THROUGH 2020 ($ MILLIONS)
  • ENZYMES
    • FIGURE 18: GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 ($ MILLIONS)
    • TABLE 106: GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH 2020 ($ MILLIONS)
  • SERVICES
    • FIGURE 19: GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 ($ MILLIONS)
    • TABLE 107: GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 12 ANALYSIS BY TECHNOLOGY

  • DNA METHYLATION
    • FIGURE 20: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 ($ MILLIONS)
    • TABLE 108: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
  • HISTONE METHYLATION AND ACETYLATION
    • FIGURE 21: GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION, 2014-2020 ($ MILLIONS)
    • TABLE 109: GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
  • MICRORNA MODIFICATION
    • FIGURE 22: GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 110: GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 13 ANALYSIS BY APPLICATION

  • ONCOLOGY
    • FIGURE 23: GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 ($ MILLIONS)
    • TABLE 111: GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
  • NON-ONCOLOGY
    • FIGURE 24: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 ($ MILLIONS)
    • TABLE 112: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION, THROUGH 2020 ($ MILLIONS)
  • CANCER DRUG TECHNOLOGY
    • DNA METHYLTRANSFERASE INHIBITORS
      • FIGURE 25: GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS, 2014-2020 ($ MILLIONS)
      • TABLE 113: GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
    • HISTONE DEACETYLASE INHIBITORS
      • FIGURE 26: GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS, 2014-2020 ($ MILLIONS)
      • TABLE 114: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
  • APPLICATION AREAS
    • DIAGNOSIS
      • FIGURE 27: GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 ($ MILLIONS)
      • TABLE 115: GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • PROGNOSIS
      • FIGURE 28: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
      • TABLE 116: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT
      • FIGURE 29: GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT, 2014-2020 ($ MILLIONS)
      • TABLE 117: GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
    • DRUG DISCOVERY
      • FIGURE 30: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
      • TABLE 118: GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 14 ANALYSIS BY PERSONALIZED MEDICINES

  • FIGURE 31: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020 ($ MILLIONS)
  • TABLE 119: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 32: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, 2014-2020 ($ MILLIONS)
  • TABLE 120: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
  • PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE
    • FIGURE 33: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, 2014-2020 ($ MILLIONS)
    • TABLE 121: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
  • HEMATOLOGICAL CANCERS
    • FIGURE 34: GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS, 2014-2020 ($ MILLIONS)
    • TABLE 122: GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • Solid Tumors
      • FIGURE 35: GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 ($ MILLIONS)
      • TABLE 123: GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION, THROUGH 2020 ($ MILLIONS)
  • GASTRIC CANCER
    • FIGURE 36: GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 ($ MILLIONS)
    • TABLE 124: GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
  • LUNG CANCER
    • FIGURE 37: GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 ($ MILLIONS)
    • TABLE 125: GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
  • PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS
    • HUNTINGTON'S DISEASE
      • FIGURE 38: GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020 ($ MILLIONS)
      • TABLE 126: GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
    • ALZHEIMER'S DISEASE
      • FIGURE 39: GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 ($ MILLIONS)
      • TABLE 127: GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION, THROUGH 2020 ($ MILLIONS)
    • DEPRESSION
      • FIGURE 40: GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 ($ MILLIONS)
      • TABLE 128: GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH 2020 ($ MILLIONS)
    • MENTAL RETARDATION
      • FIGURE 41: GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 ($ MILLIONS)
      • TABLE 129: GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION, THROUGH 2020 ($ MILLIONS)
    • PARKINSON'S DISEASE
      • FIGURE 42: GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 ($ MILLIONS)
      • TABLE 130: GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
  • PERSONALIZED MEDICINE FOR OTHERS
    • MYELODYSPLASTIC SYNDROMES
      • FIGURE 43: GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES, 2014-2020 ($ MILLIONS)
      • TABLE 131: GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES BY REGION, THROUGH 2020 ($ MILLIONS)
    • OBESITY
      • FIGURE 44: GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 ($ MILLIONS)
      • TABLE 132: GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020 ($ MILLIONS)
    • DIABETES
      • FIGURE 45: GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
      • TABLE 133: GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
    • RHEUMATOID ARTHRITIS
      • FIGURE 46: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
      • TABLE 134: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • MULTIPLE SCLEROSIS
      • FIGURE 47: GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 ($ MILLIONS)
      • TABLE 135: GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • INFLAMMATORY BOWEL DISEASES
      • FIGURE 48: GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES, 2014-2020 ($ MILLIONS)
      • TABLE 136: GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
    • LUPUS
      • FIGURE 49: GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 ($ MILLIONS)
      • TABLE 137: GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 ($ MILLIONS)
    • STEM CELL THERAPIES
      • FIGURE 50: GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 ($ MILLIONS)
      • TABLE 138: GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TISSUE RE-ENGINEERING
      • FIGURE 51: GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020 ($ MILLIONS)
      • TABLE 139: GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION, THROUGH 2020 ($ MILLIONS)
    • DIABETES
      • FIGURE 52: GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
      • TABLE 140: GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
    • RHEUMATOID ARTHRITIS
      • FIGURE 53: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
      • TABLE 141: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • MENTAL DISORDERS
      • FIGURE 54: GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 ($ MILLIONS)
      • TABLE 142: GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • CARDIAC DYSFUNCTION
      • FIGURE 55: GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020 ($ MILLIONS)
      • TABLE 143: GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION, THROUGH 2020 ($ MILLIONS)
    • CANCER
      • FIGURE 56: GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 ($ MILLIONS)
      • TABLE 144: GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
    • BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION
      • FIGURE 57: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER DETECTION, 2014-2020 ($ MILLIONS)
      • TABLE 145: GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
    • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
      • FIGURE 58: GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, 2014-2020 ($ MILLIONS)
      • TABLE 146: GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 59: GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING, 2014-2020 ($ MILLIONS)
      • TABLE 147: GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION, THROUGH 2020 ($ MILLIONS)
    • NONCODING RNAS
      • FIGURE 60: GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 ($ MILLIONS)
      • TABLE 148: GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 61: GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 ($ MILLION)
      • TABLE 149: GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 15 COMPANY PROFILES

  • ABBOTT LABORATORIES
    • TABLE 150: ABBOTT PRODUCT PORTFOLIO
    • TABLE 151: ABBOTT RECENT DEVELOPMENTS
  • AFFYMETRIX
    • TABLE 152: AFFYMETRIX PRODUCT PORTFOLIO
    • TABLE 153: AFFYMETRIX RECENT DEVELOPMENTS
  • AGILENT TECHNOLOGIES
    • TABLE 154: AGILENT PRODUCT PORTFOLIO
    • TABLE 155: AGILENT'S RECENT DEVELOPMENTS
  • ASTELLAS PHARMACEUTICALS
    • TABLE 156: ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO
    • TABLE 157: ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS
  • BAYER AG
    • TABLE 158: BAYER PRODUCT PORTFOLIO
    • TABLE 159: BAYER RECENT DEVELOPMENTS
  • BIO VISION
    • TABLE 160: BIO VISION PRODUCT PORTFOLIO
    • TABLE 161: BIO VISION RECENT DEVELOPMENTS
  • CELGENE CORP.
    • TABLE 162: CELGENE PRODUCT PORTFOLIO
  • EMD MILLIPORE
    • TABLE 163: EMD MILLIPORE PRODUCT PORTFOLIO
    • TABLE 164: EMD MILLIPORE RECENT DEVELOPMENTS
  • EPIGENOMICS AG
    • TABLE 165: EPIGENOMICS PRODUCT PORTFOLIO
    • TABLE 166: EPIGENOMICS RECENT DEVELOPMENTS
  • EPIGENTEX
    • TABLE 167: EPIGENTEK PRODUCT PORTFOLIO
    • TABLE 168: EPIGENTEK RECENT DEVELOPMENTS
  • ENVIVO PHARMACEUTICALS (FORUM PHARMACEUTRICALS)
  • GILEAD SCIENCES
    • TABLE 169: GILEAD SCIENCES PRODUCT PORTFOLIO
    • TABLE 170: GILEAD SCIENCES RECENT DEVELOPMENTS
  • GLAXOSMITHKLINE
    • TABLE 171: GLAXOSMITHKLINE PRODUCT PORTFOLIO
  • ILLUMINA INC.
    • TABLE 172: ILLUMINA PRODUCT PORTFOLIO
    • TABLE 173: ILLUMINA RECENT DEVELOPMENTS
  • JOHNSON & JOHNSON
    • TABLE 174: JOHNSON & JOHNSON PRODUCT PORTFOLIO
  • KARUS THERAPEUTICS LIMITED
    • TABLE 175: KARUS THERAPEUTICS PRODUCT PORTFOLIO
  • LABORATORY CORP. OF AMERICA HOLDINGS
    • TABLE 176: LABCORP PRODUCT PORTFOLIO
    • TABLE 177: LABCORP RECENT DEVELOPMENTS
  • LES LABORATOIRES SERVIER
    • TABLE 178: LES LABORATOIRES SERVIER RECENT DEVELOPMENTS
  • MERCK SHARP & DOHME
  • NATUREWISE BIOTECH & MEDICALS CORP.
  • NOVARTIS PHARMA AG
    • TABLE 179: NOVARTIS PRODUCT PORTFOLIO
    • TABLE 180: NOVARTIS RECENT DEVELOPMENTS
  • ONCOLYS BIOPHARMA INC.
    • TABLE 181: ONCOLYS BIOPHARMA PRODUCT PORTFOLIO
    • TABLE 182: ONCOLYS BIOPHARMA RECENT DEVELOPMENTS
  • ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
    • TABLE 183: ORCHID CHEMICALS & PHARMACEUTICALS PRODUCT PORTFOLIO
  • PROGEN PHARMACEUTICALS LIMITED
    • TABLE 184: PROGEN PHARMA PRODUCT PORTFOLIO
  • QUEST DIAGNOSTICS
    • TABLE 185: QUEST DIAGNOSTICS PRODUCT PORTFOLIO
    • TABLE 186: QUEST DIAGNOSTICS RECENT DEVELOPMENTS
  • ROCHE HOLDING AG
    • TABLE 187: ROCHE'S PRODUCT PORTFOLIO
    • TABLE 188: ROCHE'S RECENT DEVELOPMENTS
  • RUBICON GENOMICS
    • TABLE 189: RUBICON GENOMICS PRODUCT PORTFOLIO
    • TABLE 190: RUBICON GENOMICS RECENT DEVELOPMENTS
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • TABLE 191: TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO

CHAPTER 16 PATENT ANALYSIS

  • LIST OF PATENTS
  • U.S.
    • TABLE 192: U.S. PATENTS, 2011-JULY 2015
  • EUROPEAN AND JAPANESE PATENTS
    • TABLE 193: EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015
  • JAPANESE PATENTS
    • TABLE 194: JAPANESE PATENTS, 2011--NOVEMBER 2014

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES
    • TABLE 2: SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT
    • TABLE 3: EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL
    • TABLE 4: CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND DEVELOPMENTAL PHASES, 2005-2015
    • TABLE 5: FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES, 2004-2015
    • TABLE 6: CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC SYNDROMES (2015)
    • TABLE 7: EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS PATHOGENESIS
    • TABLE 8: GLOBAL CANCER INCIDENCES, 2012
    • TABLE 9: MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015
    • TABLE 10: KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED R&D, 2004-2015
    • TABLE 11: GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS)
    • TABLE 12: INDICATIONS AND OUTCOMES
    • TABLE 13: NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • TABLE 14: NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 15: NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 16: NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 17: NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
    • TABLE 18: NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 19: NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 20: NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 21: NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 22: NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 27: NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 28: NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 29: NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 30: NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 31: ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • TABLE 32: ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 33: ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 34: ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 35: ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 37: ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 38: ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY THERAPEUTIC, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 40: ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 43: ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 44: ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH ($ MILLIONS)
    • TABLE 51: EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
    • TABLE 54: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 55: EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 57: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 58: EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 60: EUROPEAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 63: EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 64: EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 65: EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 66: EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 67: LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • TABLE 68: LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 69: LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 70: LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 71: LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 72: LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 73: LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 74: LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 75: LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 76: LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 77: LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 78: LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 79: LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 80: LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 81: LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 82: LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 83: LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 84: LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 85: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • TABLE 86: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 87: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 88: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
    • TABLE 89: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
    • TABLE 90: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 91: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 92: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 93: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 94: MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
    • TABLE 95: MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 96: MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 97: MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 98: MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 99: MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 100: MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 101: MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 102: MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 103: GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 104: GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 105: GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 106: GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 107: GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 108: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 109: GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 110: GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 111: GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 112: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 113: GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 114: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 115: GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 116: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 117: GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 118: GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 119: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 120: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 121: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 122: GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 123: GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 124: GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 125: GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 126: GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 127: GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 128: GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 129: GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 130: GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 131: GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 132: GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 133: GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 134: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 135: GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 136: GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 137: GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 138: GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 139: GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 140: GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 141: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 142: GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 143: GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 144: GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 145: GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 146: GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 147: GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 148: GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 149: GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 150: ABBOTT PRODUCT PORTFOLIO
    • TABLE 151: ABBOTT RECENT DEVELOPMENTS
    • TABLE 152: AFFYMETRIX PRODUCT PORTFOLIO
    • TABLE 153: AFFYMETRIX RECENT DEVELOPMENTS
    • TABLE 154: AGILENT PRODUCT PORTFOLIO
    • TABLE 155: AGILENT'S RECENT DEVELOPMENTS
    • TABLE 156: ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO
    • TABLE 157: ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS
    • TABLE 158: BAYER PRODUCT PORTFOLIO
    • TABLE 159: BAYER RECENT DEVELOPMENTS
    • TABLE 160: BIO VISION PRODUCT PORTFOLIO
    • TABLE 161: BIO VISION RECENT DEVELOPMENTS
    • TABLE 162: CELGENE PRODUCT PORTFOLIO
    • TABLE 163: EMD MILLIPORE PRODUCT PORTFOLIO
    • TABLE 164: EMD MILLIPORE RECENT DEVELOPMENTS
    • TABLE 165: EPIGENOMICS PRODUCT PORTFOLIO
    • TABLE 166: EPIGENOMICS RECENT DEVELOPMENTS
    • TABLE 167: EPIGENTEK PRODUCT PORTFOLIO
    • TABLE 168: EPIGENTEK RECENT DEVELOPMENTS
    • TABLE 169: GILEAD SCIENCES PRODUCT PORTFOLIO
    • TABLE 170: GILEAD SCIENCES RECENT DEVELOPMENTS
    • TABLE 171: GLAXOSMITHKLINE PRODUCT PORTFOLIO
    • TABLE 172: ILLUMINA PRODUCT PORTFOLIO
    • TABLE 173: ILLUMINA RECENT DEVELOPMENTS
    • TABLE 174: JOHNSON & JOHNSON PRODUCT PORTFOLIO
    • TABLE 175: KARUS THERAPEUTICS PRODUCT PORTFOLIO
    • TABLE 176: LABCORP PRODUCT PORTFOLIO
    • TABLE 177: LABCORP RECENT DEVELOPMENTS
    • TABLE 178: LES LABORATOIRES SERVIER RECENT DEVELOPMENTS
    • TABLE 179: NOVARTIS PRODUCT PORTFOLIO
    • TABLE 180: NOVARTIS RECENT DEVELOPMENTS
    • TABLE 181: ONCOLYS BIOPHARMA PRODUCT PORTFOLIO
    • TABLE 182: ONCOLYS BIOPHARMA RECENT DEVELOPMENTS
    • TABLE 183: ORCHID CHEMICALS & PHARMACEUTICALS PRODUCT PORTFOLIO
    • TABLE 184: PROGEN PHARMA PRODUCT PORTFOLIO
    • TABLE 185: QUEST DIAGNOSTICS PRODUCT PORTFOLIO
    • TABLE 186: QUEST DIAGNOSTICS RECENT DEVELOPMENTS
    • TABLE 187: ROCHE'S PRODUCT PORTFOLIO
    • TABLE 188: ROCHE'S RECENT DEVELOPMENTS
    • TABLE 189: RUBICON GENOMICS PRODUCT PORTFOLIO
    • TABLE 190: RUBICON GENOMICS RECENT DEVELOPMENTS
    • TABLE 191: TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO
    • TABLE 192: U.S. PATENTS, 2011-JULY 2015
    • TABLE 193: EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015
    • TABLE 194: JAPANESE PATENTS, 2011--NOVEMBER 2014

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 1: AZAC AND 5-AZADC MECHANISM OF ACTION
    • FIGURE 2: EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC GENES
    • FIGURE 3: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020
    • FIGURE 4: POPULATION AGE 65 AND OLDER, 2010-2030 (%)
    • FIGURE 5: EPIGENOMIC ANALYSIS
    • FIGURE 6: POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%)
    • FIGURE 7: GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%)
    • FIGURE 8: EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES
    • FIGURE 9: EPIGENETICS MECHANISM
    • FIGURE 10: NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
    • FIGURE 11: ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
    • FIGURE 12: EUROPE EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
    • FIGURE 13: LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
    • FIGURE 14: MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
    • FIGURE 15: GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 ($ MILLIONS)
    • FIGURE 16: GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 ($ MILLIONS)
    • FIGURE 17: GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 ($ MILLIONS)
    • FIGURE 18: GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 ($ MILLIONS)
    • FIGURE 20: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 ($ MILLIONS)
    • FIGURE 21: GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION, 2014-2020 ($ MILLIONS)
    • FIGURE 22: GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 ($ MILLIONS)
    • FIGURE 24: GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 ($ MILLIONS)
    • FIGURE 25: GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS, 2014-2020 ($ MILLIONS)
    • FIGURE 26: GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS, 2014-2020 ($ MILLIONS)
    • FIGURE 27: GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 ($ MILLIONS)
    • FIGURE 28: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
    • FIGURE 29: GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT, 2014-2020 ($ MILLIONS)
    • FIGURE 30: GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
    • FIGURE 31: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020 ($ MILLIONS)
    • FIGURE 32: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, 2014-2020 ($ MILLIONS)
    • FIGURE 33: GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, 2014-2020 ($ MILLIONS)
    • FIGURE 34: GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS, 2014-2020 ($ MILLIONS)
    • FIGURE 35: GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 ($ MILLIONS)
    • FIGURE 36: GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 ($ MILLIONS)
    • FIGURE 37: GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 ($ MILLIONS)
    • FIGURE 38: GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020 ($ MILLIONS)
    • FIGURE 39: GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 ($ MILLIONS)
    • FIGURE 40: GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 ($ MILLIONS)
    • FIGURE 41: GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 ($ MILLIONS)
    • FIGURE 42: GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 ($ MILLIONS)
    • FIGURE 43: GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES, 2014-2020 ($ MILLIONS)
    • FIGURE 44: GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 ($ MILLIONS)
    • FIGURE 45: GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
    • FIGURE 46: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
    • FIGURE 47: GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 ($ MILLIONS)
    • FIGURE 48: GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES, 2014-2020 ($ MILLIONS)
    • FIGURE 49: GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 ($ MILLIONS)
    • FIGURE 50: GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 ($ MILLIONS)
    • FIGURE 51: GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020 ($ MILLIONS)
    • FIGURE 52: GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
    • FIGURE 53: GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
    • FIGURE 54: GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 ($ MILLIONS)
    • FIGURE 55: GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020 ($ MILLIONS)
    • FIGURE 56: GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 ($ MILLIONS)
    • FIGURE 57: GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER DETECTION, 2014-2020 ($ MILLIONS)
    • FIGURE 58: GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, 2014-2020 ($ MILLIONS)
    • FIGURE 59: GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING, 2014-2020 ($ MILLIONS)
    • FIGURE 60: GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 ($ MILLIONS)
    • FIGURE 61: GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 ($ MILLION)
Back to Top